Home › Multiple Myeloma › Delaware › Newark
Multiple Myeloma clinical trials in Newark, DE
3 studies for Multiple Myeloma are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- Medical Oncology Hematology Consultants /ID# 268560, Newark
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
RecruitingPhase 2
- Medical Oncology Hematology Consultants, Newark
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY59 studies
- Boston, MA45 studies
- Atlanta, GA42 studies
- Houston, TX39 studies
- Durham, NC36 studies
- Nashville, TN31 studies
- Denver, CO26 studies
- St. Louis, MO26 studies
- Rochester, MN25 studies
- Columbus, OH25 studies
- Chicago, IL24 studies
- Milwaukee, WI23 studies
Other studies in Newark
- Non-Small Cell Lung Cancer15 studies
- Prostate Cancer10 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Metastatic Cancer8 studies
- Breast Cancer8 studies
- Pancreatic Cancer6 studies
- Cancer (all types)6 studies
- Ovarian Cancer5 studies
- Bladder Cancer4 studies
- Chronic Lymphocytic Leukemia4 studies
- Stomach Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.